MX360498B - Compuesto novedoso de pirimidina fusionada o sal del mismo. - Google Patents

Compuesto novedoso de pirimidina fusionada o sal del mismo.

Info

Publication number
MX360498B
MX360498B MX2016001845A MX2016001845A MX360498B MX 360498 B MX360498 B MX 360498B MX 2016001845 A MX2016001845 A MX 2016001845A MX 2016001845 A MX2016001845 A MX 2016001845A MX 360498 B MX360498 B MX 360498B
Authority
MX
Mexico
Prior art keywords
salt
pyrimidine compound
fused pyrimidine
present
novel fused
Prior art date
Application number
MX2016001845A
Other languages
English (en)
Other versions
MX2016001845A (es
Inventor
Satoru Iguchi
Takeshi Sagara
Hosoi Fumihito
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2016001845A publication Critical patent/MX2016001845A/es
Publication of MX360498B publication Critical patent/MX360498B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se proporciona un compuesto novedoso que tiene acción inhibidora de BTK y un efecto de supresión de la proliferación celular; también se proporciona un medicamento útil para la prevención y/o tratamiento de una enfermedad relacionada con BTK, particularmente cáncer, con base en la acción inhibidora de BTK; se describe un compuesto representado por la fórmula (I) [en donde R1 a R3, W, A, Y y Z respectivamente tienen los significados como se definió en la especificación], o una sal del mismo. (ver Fórmula).
MX2016001845A 2013-08-12 2014-08-11 Compuesto novedoso de pirimidina fusionada o sal del mismo. MX360498B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013167600 2013-08-12
PCT/JP2014/071158 WO2015022926A1 (ja) 2013-08-12 2014-08-11 新規な縮合ピリミジン化合物又はその塩

Publications (2)

Publication Number Publication Date
MX2016001845A MX2016001845A (es) 2016-05-16
MX360498B true MX360498B (es) 2018-11-05

Family

ID=52468312

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001845A MX360498B (es) 2013-08-12 2014-08-11 Compuesto novedoso de pirimidina fusionada o sal del mismo.

Country Status (22)

Country Link
US (1) US9580432B2 (es)
EP (1) EP2947086B1 (es)
JP (1) JP6035423B2 (es)
KR (1) KR101828187B1 (es)
CN (1) CN105452257B (es)
AU (1) AU2014307437B2 (es)
BR (1) BR112016002069B1 (es)
CA (1) CA2921208C (es)
DK (1) DK2947086T3 (es)
ES (1) ES2661733T3 (es)
HU (1) HUE036834T2 (es)
MX (1) MX360498B (es)
MY (1) MY171831A (es)
NO (1) NO2947086T3 (es)
PH (1) PH12015502737B1 (es)
PL (1) PL2947086T3 (es)
PT (1) PT2947086T (es)
RU (1) RU2666349C2 (es)
SG (1) SG11201600048VA (es)
TR (1) TR201802875T4 (es)
TW (1) TWI585089B (es)
WO (1) WO2015022926A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3035936T3 (da) 2013-08-23 2019-06-11 Neupharma Inc Visse kemiske enheder, sammensætninger og fremgangsmåder
DK3120852T3 (da) * 2015-01-30 2019-07-29 Taiho Pharmaceutical Co Ltd Præventivt og/eller terapeutisk middel til immunsygdomme
WO2016121954A1 (ja) * 2015-01-30 2016-08-04 大鵬薬品工業株式会社 縮合ピリミジン化合物の新規な塩及びその結晶
ES2799520T3 (es) 2015-09-01 2020-12-18 Taiho Pharmaceutical Co Ltd Compuestos de pirazolo[3,4-d]pirimidina o sales de los mismos
MA41559A (fr) * 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
TWI642671B (zh) * 2015-10-28 2018-12-01 台灣神隆股份有限公司 依魯替尼之製備方法及其中間體
IL261107B2 (en) 2016-02-23 2023-11-01 Taiho Pharmaceutical Co Ltd A novel compressed pyrimidine compound or a salt thereof
EP3497087B1 (en) * 2016-08-15 2021-11-10 Neupharma, Inc. Pyrrolo[1,2-c]pyrimidine, imidazo[1,5-c]pyrimidine, quinazoline, purine and imidazo[1,5-a][1,3,5]triazine derivatives as tyrosine kinase inhibitors for the treatment of cancer
KR102674711B1 (ko) * 2017-02-28 2024-06-12 다이호야쿠힌고교 가부시키가이샤 피라졸로[3,4-d]피리미딘 화합물을 사용한 항종양 효과 증강제
SG11202001212SA (en) 2017-08-21 2020-03-30 Taiho Pharmaceutical Co Ltd Fusion protein of dctn1 protein with ret protein
PT3909584T (pt) * 2019-01-11 2024-01-12 Taiho Pharmaceutical Co Ltd Composto de pirimidina ou um seu sal
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021125313A1 (ja) 2019-12-19 2021-06-24 大鵬薬品工業株式会社 縮合ピリミジン化合物を有効成分とする治療剤
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP7373664B2 (ja) * 2020-07-15 2023-11-02 大鵬薬品工業株式会社 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN114736207B (zh) * 2022-04-28 2023-03-31 武汉九州钰民医药科技有限公司 一种小分子her2抑制剂的制备工艺

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680436A1 (en) 2003-10-27 2006-07-19 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CN101336244B (zh) 2005-12-08 2011-11-30 雅培制药有限公司 用作蛋白激酶抑制剂的9元杂二环化合物
EP2007373A4 (en) 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
ES2403546T3 (es) * 2006-11-03 2013-05-20 Pharmacyclics, Inc. Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
SG10201508035TA (en) * 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
JP2009235057A (ja) * 2007-10-31 2009-10-15 Santen Pharmaceut Co Ltd 血管新生阻害活性を有する新規インドール誘導体
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EA201490265A1 (ru) * 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
CN103717247B (zh) * 2011-07-15 2016-04-27 赛诺菲-安万特德国有限公司 药物输送装置
MX351513B (es) 2012-01-19 2017-10-17 Taiho Pharmaceutical Co Ltd Compuesto de alquinilbenceno 3,5-disustituido y sales del mismo.
CN104250250A (zh) * 2013-06-25 2014-12-31 苏州科捷生物医药有限公司 4-芳香胺基嘧啶类化合物及其抗肿瘤用途

Also Published As

Publication number Publication date
CN105452257A (zh) 2016-03-30
US9580432B2 (en) 2017-02-28
AU2014307437A1 (en) 2016-01-21
BR112016002069A2 (pt) 2017-08-01
PH12015502737B1 (en) 2018-08-31
CN105452257B (zh) 2017-09-05
NO2947086T3 (es) 2018-06-02
HUE036834T2 (hu) 2018-08-28
AU2014307437B2 (en) 2016-12-15
JP6035423B2 (ja) 2016-11-30
MY171831A (en) 2019-11-01
ES2661733T3 (es) 2018-04-03
HK1217703A1 (zh) 2017-01-20
EP2947086A4 (en) 2016-06-22
RU2666349C2 (ru) 2018-09-07
TR201802875T4 (tr) 2018-03-21
SG11201600048VA (en) 2016-03-30
DK2947086T3 (en) 2018-03-19
KR20160038891A (ko) 2016-04-07
EP2947086B1 (en) 2018-01-03
KR101828187B1 (ko) 2018-02-09
BR112016002069B1 (pt) 2020-08-18
PH12015502737A1 (en) 2016-03-07
CA2921208C (en) 2018-02-20
TW201536786A (zh) 2015-10-01
PL2947086T3 (pl) 2018-06-29
EP2947086A1 (en) 2015-11-25
US20160115168A1 (en) 2016-04-28
JPWO2015022926A1 (ja) 2017-03-02
MX2016001845A (es) 2016-05-16
WO2015022926A1 (ja) 2015-02-19
RU2015156524A (ru) 2017-09-14
CA2921208A1 (en) 2015-02-19
PT2947086T (pt) 2018-03-09
TWI585089B (zh) 2017-06-01

Similar Documents

Publication Publication Date Title
PH12015502737A1 (en) Novel fused pyrimidine compound or salt thereof
MX2022002579A (es) Compuestos de aminotiazol como inhibidores de c- kit.
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
PH12017502363A1 (en) Brk inhibitory compound
MX2015010125A (es) Derivados de piridazinona-amidas.
MX373865B (es) Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo
MD20160106A2 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
PH12016500225B1 (en) Novel quinoline-substituted compound
MD4666B1 (ro) Inhibitori ai Syk
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
BR112015000399A2 (pt) derivados de pirazolil pirimidina
MX367897B (es) Derivados de piridazinona macrociclicos.
PH12014502396B1 (en) Nitrogenated heterocyclic compound
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
MX352928B (es) Compuestos de piridazina-amida.
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
EP3587400A3 (en) Process for the preparation of a pde4 inhibitor
MX349548B (es) Compuestos de tienopirimidina.
EA201790207A8 (ru) Новые замещенные пиримидиновые соединения
MX366839B (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde4.
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.
MX2017000522A (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde.
MX394038B (es) Derivados de pirrolotriazina como inhibidores de cinasas.
PH12017500492A1 (en) Crystalline bace inhibitors

Legal Events

Date Code Title Description
FG Grant or registration